Page 132 - Demo

Appendix130Publications included in this thesisPhase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. A.A. van Zweeden, H.J. van der Vliet, J.W. Wilmink, M.R. Meijerink, O.W. Meijer, A.M. Bruynzeel, G. van Tienhoven, E. Giovannetti, G. Kazemier, M.A.Jacobs, H.M.W. VerheulClin Cancer Res. 2015 Oct 15;21(20):4569-75. doi: 10.1158/1078-0432.CCR-14-3364. Epub 2015 Jun 8. PMID: 26056353.Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. A.A. van Zweeden, C.J. van Groeningen, R.J. Honeywell, E. Giovannetti, R. Ruijter, C.H. Smorenburg, G. Giaccone, H.M.W. Verheul, G.J. Peters, H.J. van der VlietCancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25. PMID: 29696360; PMCID: PMC6010482. The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. A.A. van Zweeden, R.C.M. Opperman, R.J. Honeywell, G.J. Peters, H.M.W. Verheul, H.J. van der Vliet, D. PoelCancer Treat Res Commun. 2021;27:100371. doi: 10.1016/j.ctarc.2021.100371. Epub 2021 Apr 9. PMID: 33866108.